Envestnet Asset Management Inc. Has $5.67 Million Position in SPDR S&P Biotech ETF $XBI

Envestnet Asset Management Inc. lowered its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 9.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 56,611 shares of the exchange traded fund’s stock after selling 5,743 shares during the period. Envestnet Asset Management Inc. owned 0.09% of SPDR S&P Biotech ETF worth $5,672,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in shares of SPDR S&P Biotech ETF by 2.6% in the second quarter. JPMorgan Chase & Co. now owns 10,638,105 shares of the exchange traded fund’s stock valued at $882,218,000 after buying an additional 268,399 shares in the last quarter. Bessemer Group Inc. boosted its holdings in shares of SPDR S&P Biotech ETF by 4.4% in the 2nd quarter. Bessemer Group Inc. now owns 1,494,666 shares of the exchange traded fund’s stock worth $123,951,000 after buying an additional 62,600 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of SPDR S&P Biotech ETF by 123.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock valued at $72,542,000 after acquiring an additional 481,408 shares during the period. Meitav Investment House Ltd. increased its position in SPDR S&P Biotech ETF by 70.3% in the third quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock worth $68,156,000 after buying an additional 281,602 shares during the last quarter. Finally, Greenhouse Funds LLLP boosted its position in SPDR S&P Biotech ETF by 17.3% during the second quarter. Greenhouse Funds LLLP now owns 579,667 shares of the exchange traded fund’s stock worth $48,072,000 after purchasing an additional 85,422 shares during the period.

SPDR S&P Biotech ETF Price Performance

SPDR S&P Biotech ETF stock opened at $124.78 on Friday. The firm has a market capitalization of $8.34 billion, a P/E ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a one year low of $66.66 and a one year high of $132.09. The business has a fifty day moving average price of $124.65 and a 200-day moving average price of $111.25.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.